Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86

Key Points

• Bicara Therapeutics Inc. (NASDAQ:BCAX) has an average analyst rating of "Buy" from nine brokerages, with a consensus price target of $31.86.
• The company's stock price remained flat at $10.20 during recent trading, with a 12-month range between $7.80 and $28.09.
• In its latest earnings report, Bicara Therapeutics missed consensus estimates, reporting an EPS of ($0.68) against projections of ($0.40).

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been assigned a consensus rating of "Buy" from the nine analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $31.8586.

Several equities analysts have commented on the stock. HC Wainwright decreased their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target for the company in a research report on Friday, May 23rd. Wedbush reissued an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Finally, Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its stake in Bicara Therapeutics by 28.7% during the 4th quarter. Millennium Management LLC now owns 385,406 shares of the company's stock worth $6,714,000 after acquiring an additional 85,847 shares in the last quarter. Northern Trust Corp acquired a new stake in Bicara Therapeutics during the 4th quarter worth $2,771,000. Deutsche Bank AG acquired a new stake in Bicara Therapeutics during the 4th quarter worth $1,959,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics during the 4th quarter worth $33,000. Finally, Bank of America Corp DE raised its stake in Bicara Therapeutics by 278.4% during the 4th quarter. Bank of America Corp DE now owns 33,677 shares of the company's stock worth $587,000 after acquiring an additional 24,777 shares in the last quarter.

Bicara Therapeutics Stock Performance

BCAX stock traded down $0.55 during midday trading on Friday, hitting $9.65. The company's stock had a trading volume of 27,447 shares, compared to its average volume of 612,250. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $28.09. The firm has a 50-day simple moving average of $10.43 and a 200-day simple moving average of $11.98.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, research analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.